Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Altimmune (ALT) over the last 17 years, with Q3 2025 value amounting to -$11.9 million.

  • Altimmune's Free Cash Flow rose 5612.88% to -$11.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$66.4 million, marking a year-over-year increase of 1505.97%. This contributed to the annual value of -$79.8 million for FY2024, which is 526.12% down from last year.
  • According to the latest figures from Q3 2025, Altimmune's Free Cash Flow is -$11.9 million, which was up 5612.88% from -$19.3 million recorded in Q2 2025.
  • Altimmune's Free Cash Flow's 5-year high stood at -$11.9 million during Q3 2025, with a 5-year trough of -$27.1 million in Q3 2024.
  • For the 5-year period, Altimmune's Free Cash Flow averaged around -$18.8 million, with its median value being -$18.1 million (2024).
  • Its Free Cash Flow has fluctuated over the past 5 years, first plummeted by 44467.59% in 2021, then surged by 5612.88% in 2025.
  • Altimmune's Free Cash Flow (Quarter) stood at -$22.1 million in 2021, then grew by 21.57% to -$17.3 million in 2022, then rose by 4.68% to -$16.5 million in 2023, then fell by 10.48% to -$18.3 million in 2024, then skyrocketed by 34.86% to -$11.9 million in 2025.
  • Its Free Cash Flow was -$11.9 million in Q3 2025, compared to -$19.3 million in Q2 2025 and -$16.8 million in Q1 2025.